Wolfe Research has upgraded Bruker Corp (BRKR) to an Outperform rating, a change from its previous Peer Perform designation. This adjustment, effective December 9, 2025, suggests a more optimistic outlook regarding the company's performance.
Bruker Corp, headquartered in Billerica, Massachusetts, operates in the life sciences tools and services industry. The company develops and distributes high-performance scientific instruments and analytical solutions that aid customers in exploring life and materials at various levels of detail. Currently, Bruker employs 11,396 full-time staff and has a market capitalization of $6.9 billion. The firm reported an earnings per share (EPS) of -0.14 over the trailing twelve months and offers a dividend yield of 43.5%.
Looking ahead, Bruker is set to announce its next earnings report on August 3, 2026, with an expected EPS of $0.43 and projected revenue of $832.6 million. The recent upgrade from Wolfe Research underscores a shift in analyst sentiment, potentially reflecting improved fundamentals or business performance.
As of December 1, 2025, the consensus among analysts remains a Buy, with six Strong Buy ratings, six Buy ratings, and eight Hold ratings. Analyst opinions can vary, and it is important for investors to consider multiple factors, including company fundamentals and industry trends, when making investment decisions.
This update provides insight into the evolving perspective on Bruker Corp's potential, as reflected in recent analyst actions, including an initiation to Sell by Goldman Sachs on December 9, 2025, and a Buy rating from Rothschild & Co on November 20, 2025.